FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 08/2024”. The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the tip of August 2024 we recognized the next present VC traits in Europe:
- Complete Healthcare & Life Sciences funding reached EUR 5,581m
- Biotech acquired 58% of the entire funding quantity (EUR 3,218m) with oncology being the main indication (48%)
- August noticed little or no VC exercise in Europe (EUR 133m) with Healx (United Kingdom) securing the very best transaction quantity with EUR 43m, adopted by Hexarad (United Kingdom) with EUR 13m and Vandria (Switzerland) with EUR 11m
- Normal Atlantic (United States) is essentially the most energetic investor (by deal quantity), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the total report, please click on right here.
